Ixekizumab improved psoriatic arthritis in patients who had not taken biologics

Two different doses of the humanized monoclonal antibody ixekizumab improved signs and symptoms of active psoriatic arthritis in a phase III manufacturer-sponsored trial of patients who had not taken a biologic drug before. The agent selectively binds and neutralizes interleukin (IL)-17A, which...
Source: Skin and Allergy News - Category: Dermatology Source Type: news